Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Wayne Liang
Assistant Professor
Close
E-mail
wliang@uab.edu
Phone
205-638-3000
Links
Twitter
Doximity
LinkedIn
Provider Directory
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Wayne Liang
Assistant Professor
Positions
Associate Scientist
,
Experimental Therapeutics
,
O'Neal Comprehensive Cancer Center
Scientist (C)
,
Informatics Institute
,
School of Medicine
2017 -
Assistant Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
2017 -
Associate Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
2017 -
Scientist (C)
,
Personalized Medicine Institute
,
School of Medicine
2017 -
Associate Scientist (C)
,
Center for Clinical and Translational Science (CCTS)
,
General Clinical Research Center
2020 -
Publications
Research
Teaching
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2020
Tailoring therapy for children with neuroblastoma on the basis of risk group classification: Past, present, and future
.
JCO Clinical Cancer Informatics
. 895-905.
2020
2018
Empowering genomic medicine by establishing critical sequencing result data flows: The eMERGE example
.
Journal of the American Medical Informatics Association
. 25:1375-1381.
2018
2018
Development of a Technology-Supported, Lay Peer-to-Peer Family Engagement Consultation Service in a Pediatric Hospital
.
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium
. 2018:730-739.
2018
2018
Phenotype Detection Registry System (PheDRS) - Implementation of a Generalizable Single Institution Clinical Registry Architecture
.
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium
. 2018:847-856.
2018
2015
Wheezing is common in children with sickle cell disease when compared with controls
.
Journal of Pediatric Hematology/Oncology
. 37:16-19.
2015
2014
Clinically significant hemolytic disease of the newborn secondary to passive transfer of anti-D from maternal RhIG.
.
Transfusion
. 54:2863-2866.
2014
2008
Who receives house calls?
.
Journal of the American Geriatrics Society
. 56:1581-1582.
2008
Research
Principal Investigator On
Pediatric Cancer Data Commons
awarded by
University of Chicago ^
2020 - 2021
Investigator On
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2020 - 2026
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2021 - 2026
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Cookies for Kids' Cancer Phase 1 Supplemental
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2025
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
2020 - 2025
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2024
ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network
awarded by
CDC - Centers for Disease Control and Prevention/DHHS
2020 - 2023
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2023
NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
2017 - 2022
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2022
PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
2017 - 2022
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2022
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
2019 - 2022
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
2018 - 2021
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2021
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2021
CTSU: Phase ll Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2021
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2020
NIH COG Phase I Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2020
St. Baldrick's Foundation Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2020
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2019
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2019
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2019
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2019
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2015 - 2018
Private Grant
awarded by
Bayer AG
2018
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018
Teaching
Teaching Activities
INFO696 - Biomed Informatics Methods I (Spring Term 2020)
2020
Background
Education And Training
Master of Science in Medical Informatics,
University of Washington
2017
Doctor of Medicine,
Case Western Reserve University
2010
Monroe Carell Jr. Children's Hospital at Vanderbilt, Residency
2013
Seattle Children's Hospital/Fred Hutchinson Cancer Research Center/Univ of Washington, Postdoctoral Fellowship
2017
Contact
Full Name
Wayne
Liang